CDMO:NSD-Avid Bioservices, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 25.60

Change

-0.49 (-1.88)%

Market Cap

USD 1.59B

Volume

0.27M

Avg Analyst Target

USD 25.40 (-0.78%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+2.37 (+0.74%)

USD128.93B 215.22 167.82
BNTX BioNTech SE

+21.37 (+8.23%)

USD62.70B 47.24 36.74
REGN Regeneron Pharmaceuticals, Inc

+3.16 (+0.54%)

USD62.19B 16.62 13.12
VRTX Vertex Pharmaceuticals Incorpo..

-0.25 (-0.13%)

USD50.81B 18.71 13.00
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.34B 59.23 41.97
BGNE BeiGene, Ltd

+15.11 (+4.93%)

USD29.15B N/A N/A
GMAB Genmab A/S

+0.21 (+0.48%)

USD28.86B 32.84 3.64
SGEN Seagen Inc

-0.27 (-0.19%)

USD26.06B 40.07 36.19
RPRX Royalty Pharma plc

-0.95 (-2.30%)

USD25.34B 34.40 14.43
ALNY Alnylam Pharmaceuticals, Inc

+1.72 (+0.96%)

USD21.17B N/A N/A

ETFs Containing CDMO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 121.84% 95% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 121.84% 95% A 96% A
Trailing 12 Months  
Capital Gain 266.76% 96% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 266.76% 96% A 95% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 54.03% 77% C+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.03% 77% C+ 87% B+
Risk Return Profile  
Volatility (Standard Deviation) 89.05% 32% F 18% F
Risk Adjusted Return 60.68% 86% B 77% C+
Market Capitalization 1.59B 80% B- 72% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 457.72 3% F 3% F
Price/Book Ratio 19.88 8% F 6% F
Price / Cash Flow Ratio 51.12 3% F 9% F
EV/EBITDA 94.39 10% F 11% F
Management Effectiveness  
Return on Equity 18.74% 95% A 87% B+
Return on Invested Capital 11.08% 89% B+ 81% B-
Return on Assets 4.10% 93% A 77% C+
Debt to Equity Ratio 124.72% 10% F 16% F
Technical Ratios  
Short Ratio 6.41 29% F 16% F
Short Percent 8.66% 36% F 23% F
Beta 2.22 14% F 10% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.